4DMedical Receives EU Approval for New Lung Imaging Technology
4DMedical 新型肺部影像技術獲歐盟批准
In March 2026, the Australian company 4DMedical reached a significant milestone by securing CE Mark certification for its innovative lung imaging technology, CT:VQ™.
2026年3月，澳洲公司4DMedical取得了一項重大里程碑，即為其創新的肺部成像技術CT:VQ™獲得了CE標誌認證。
This regulatory approval is a major step forward, enabling the company to introduce its product across the European Union.
這項監管批准是邁向未來的一大步，使該公司能夠在歐盟（ㄡㄇㄥˊ）各地引進其產品。
Unlike traditional nuclear medicine, CT:VQ™ is a non-invasive solution that creates detailed functional lung insights using standard, non-contrast CT scans.
與傳統核醫學不同，CT:VQ™是一種非侵入性（ㄖㄨˋㄧㄥˋㄒㄧㄥˋ）的解決方案，利用標準的非對比CT掃描，能建立詳細的肺部功能洞察。
This entry into the EU market—a region with over 450 million people—is a key part of 4DMedical's global expansion strategy.
這次進入歐盟市場——一個擁有超過4.5億人口的地區——是4DMedical全球擴張策略的關鍵部分。
Following successful adoption in prestigious U.S. institutions like the Mayo Clinic and Stanford, the company is well-positioned for international growth.
繼在梅奧診所（Mayo Clinic）和史丹佛（Stanford）等著名美國機構成功採用後，該公司已為國際成長做好了準備。
To support this rollout, 4DMedical successfully raised AU$83 million from institutional investors.
為支援此項推廣，4DMedical成功向機構投資者募集了8300萬澳元。
Founded in 2013 by Dr.
4DMedical由Andreas Fouras博士於2013年創立，持續引領將人工智慧整合至心胸成像領域，以改善全球呼吸系統疾病的診斷與管理。
Andreas Fouras, 4DMedical continues to lead the way in integrating artificial intelligence into cardiothoracic imaging to improve the diagnosis and management of respiratory conditions worldwide.
